Product Images Aripiprazole

This text provides information on the effect of certain drugs on aripiprazole metabolism, including inhibitors like ketoconazole and quinidine, an inducer like carbamazepine, and other medications like famotidine, valproate, and lorazepam. It also mentions parameters like PK, AUC, and Cmax, and provides data on the dehydro-aripiprazole fold change.*

This is a description of the effect of Aripiprazole on other drugs, specifically showing the fold change and 90% Confidence Interval of CY2s with various drugs such as Oreses, Zors, and OWOR. The text also mentions AUC values for drugs like Varlapan, Svartram, Valproate, Lorazepam, Venlafaxine, and others. The data presented in the text provides insights into the impact of Aripiprazole on these drugs in terms of their metabolism and bioavailability.*

This text seems to be discussing special populations, including gender, age, hepatic impairment, and aripiprazole food change. It provides information on how these populations may impact metabolic activity and drug responses. It also includes details about a 0% C1 change relative to a reference, which might be related to drug effects or study outcomes.*

This text appears to be describing some statistical data related to a comparison between female and male subjects across different age groups. It also mentions measurements related to "Dehydro-Aripiprazole Fold Change" with a 90% confidence interval. The data seems to involve changes relative to a reference point and potentially includes values up to 30.*

This text presents data on the drug Avipiprazole compared to Placebo in terms of relapse rates over a period of days from randomization. It shows the number of subjects at risk for each drug at different time points. The information provided can be used to analyze the efficacy of Avipiprazole versus Placebo in preventing relapses in a clinical trial.*

This is an evaluation of the proportion of subjects experiencing a relapse in a study comparing Aripiprazole with Placebo. The table provided shows the number of subjects at risk on different days from randomization.*

Description: This text provides information on the effect of different drugs on the pharmacokinetics (PK) of Aripiprazole. It includes data on fold change and 90% Confidence Intervals (Cl) for Aripiprazole when combined with CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blockers like famotidine, and others. The text also mentions the changes in Aripiprazole's AUC (area under the curve) and Cmax (maximum plasma concentration) under the influence of these interacting drugs.*

This text provides a visual representation of the least-squares mean change in YGTSS Total TIC Score over weeks of treatment for Aripiprazole low dose, Aripiprazole high dose, and placebo groups. The graph shows the change in scores from baseline, with data points for each treatment group plotted at different time intervals.*